carmustine has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moore, JJ | 1 |
| Massey, JC | 1 |
| Ford, CD | 1 |
| Khoo, ML | 1 |
| Zaunders, JJ | 1 |
| Hendrawan, K | 1 |
| Barnett, Y | 1 |
| Barnett, MH | 1 |
| Kyle, KA | 1 |
| Zivadinov, R | 1 |
| Ma, KC | 1 |
| Milliken, ST | 1 |
| Sutton, IJ | 1 |
| Ma, DDF | 1 |
1 trial available for carmustine and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; | 2019 |